Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Lonial Discusses Dramatic Progress in Multiple Myeloma

March 8th 2017

Sagar Lonial, MD, discusses recent advances that have revolutionized the treatment of patients with multiple myeloma.

Pan-Kinase Inhibition Key to Midostaurin Benefit in AML

March 7th 2017

FLT3 targeted agents are emerging in the treatment of acute myeloid leukemia, and which specific agent will be most effective is highly dependent on whether a patient has been previously treated.

FDA Lifts Clinical Hold on Vadastuximab Talirine Trials in AML

March 6th 2017

The FDA has lifted its clinical hold on several phase I trials of the antibody-drug conjugate vadastuximab talirine (SGN-CD33A) in acute myeloid leukemia.

Expert Discusses JCAR017 CAR T-Cell Therapy in Non-Hodgkin Lymphoma

March 6th 2017

Leo I. Gordon MD, discusses results from the TRANSCEND trial and the next steps with chimeric antigen receptor T-cell therapy in non-Hodgkin lymphoma.

Juno Accelerates Development of JCAR017, Halts JCAR015

March 2nd 2017

Juno therapeutics has shifted its focus toward the development of JCAR017 for relapsed/refractory diffuse large B-cell lymphoma after a series of toxicity-related setbacks culminated in the need to halt the development of JCAR015.

NEJM Data Highlight Blinatumomab OS Benefit in Acute Lymphoblastic Leukemia

March 2nd 2017

Treatment with blinatumomab (Blincyto) led to a median overall survival of 7.7 months versus 4 months with standard chemotherapy in patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia, according to results from the phase III TOWER study published in The New England Journal of Medicine.

Ibrutinib Benefit in Waldenstrom Macroglobulinemia Sustained With Latest Data

March 2nd 2017

Single-agent ibrutinib induced a response rate of 90% at a median follow-up of 18.1 months in rituximab-refractory patients with Waldenstrom macroglobulinemia, according to results from an open-label substudy of the ongoing phase III iNNOVATE trial published in The Lancet Oncology.

FDA Grants Priority Review to Enasidenib for IDH2-Mutant AML

March 1st 2017

The FDA has granted a priority review to a new drug application for enasidenib as a treatment for patients with relapsed or refractory IDH2-mutated acute myeloid leukemia.

Pivotal Year Looms for CAR T-Cell Therapies

March 1st 2017

Chimeric antigen receptor T-cell therapies have already produced clinical trial results that, even by the lofty standards set by emerging immunotherapies, have been stunning.

Genomic Advances Pave the Way for New Therapies in AML

March 1st 2017

In an OncLive Peer Exchange® panel, experts discussed novel cytotoxic and targeted agents in the pipeline that are likely to provide new options for treating certain individuals with acute myeloid leukemia.

Axicabtagene Ciloleucel Shows High CR Rates in Primary Analysis of ZUMA-1 Study

February 28th 2017

Treatment with axicabtagene ciloleucel demonstrated an objective response rate of 82% and a complete response rate of 54% for patients with aggressive non-Hodgkin lymphoma.

Dr. Garfall on CAR T Cells in ALL

February 28th 2017

Alfred L. Garfall, MD, MS, assistant professor of Medicine at the Hospital of the University of Pennsylvania, discusses CAR T-cells in acute lymphoblastic leukemia (ALL).

Dr. Fanale on Clinical Trials for T-Cell Lymphoma

February 28th 2017

Michelle A. Fanale, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses clinical trials for potential treatments for patients with T-cell lymphoma.

Axicabtagene Ciloleucel Shows Response Rate of 76% in Aggressive Lymphoma

February 27th 2017

Axicabtagene ciloleucel had an objective response rate of 76% and a complete response rate of 47% in patients with aggressive non-Hodgkin lymphoma followed for at least 1 month.

Dr. Locke on the ZUMA-1 Trial of KTE-C19 for Lymphoma

February 26th 2017

Fred Locke, MD, Moffitt Cancer Center discusses the interim results of the ZUMA-I trial of Kte-C19, a CAR T-cell therapy.

Dr. Scott on Conditioning Regimens for Stem Cell Transplants

February 26th 2017

Bart Scott, MD, Fred Hutchinson Cancer Research Center, explains the importance of the intensity of conditioning for stem cell transplants.

Researchers Examine Acquired Mutations Linked to Ibrutinib Resistance in CLL

February 25th 2017

Researchers hope the acquired ibrutinib resistance mutations BTK and PLCG2 can be used as biomarkers for early intervention opportunities in patients with chronic lymphocytic leukemia.

Vaccine Limits Herpes Zoster Infections Following Stem Cell Transplant

February 25th 2017

Treatment with an inactivated varicella zoster virus vaccine, known as V212, lowered the cumulative incidence rate of herpes zoster infection and complications for patients undergoing autologous hematopoietic stem cell transplantation.

Outcomes Have Improved Over Time in Myeloma Patients Relapsing Early After ASCT

February 25th 2017

Rates of early relapse post-autologous stem cell transplant in patients with relapsing multiple myeloma have not changed over time, but post-relapse survival among early relapsers has improved for patients transplanted after 2005 and for those relapsing since 2008.

Dr. Lancet on CPX-351 Compared to Chemotherapy for Older Adults With AML

February 25th 2017

Dr. Lancet of Moffitt Cancer Center explains the use of CPX-351 treatment compared to induction chemotherapy, for older adult patients with acute myeloid leukemia.